Consumer Health

Analgesics is set to see a decline in sales in 2023 as consumers have migrated away from aspirin in an uncertain economic environment and sought to prioritise household essentials, while turning to other categories to treat basic ailments such as…

Upon the lifting of all COVID-19 related regulations, including the compulsory use of face masks, social distancing rules and compulsory self-isolation, there has been a surge in illness which has been a major contributor to sales growth for…

Consumption of analgesics continued to increase in Germany during 2023, after the demand spike in 2022, a year in which consumers were often experiencing flu and colds in the post-pandemic period and therefore OTC medicines, such as analgesics, were…

Analgesics is expected to register moderate constant value growth in 2023. High inflation is continuing to have an effect and consumers are expected to be highly price sensitive and prioritise value for money. That being said, inflation is easing in…

Value sales of analgesics in France continue to record solid growth in 2023 following a dynamic performance the previous year. The key growth driver is the increasing demand for acetaminophen, with the brand Doliprane from Sanofi, convincingly…